Maxim Group Reiterates Buy Rating on CNTX, Sets $4 Price Target
Maxim Group maintains a buy rating on CNTX with a $4 price target, as the stock trades near $0.679, a 489.10% upside from the current price.
Key Points
- Maxim Group reiterated its buy rating on CNTX with a $4 price target on June 16, 2026.
- Maxim Group's $4 price target implies 489.10% upside from Context Therapeutics Inc.'s ($CNTX) current $0.68 share price.
- CNTX shares are trading around $0.68, with insider activity showing recent purchases by top executives.
- Institutional investors like Soleus Capital and Octagon Capital have shown interest in CNTX, adjusting their holdings recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Maxim Group has reiterated its buy rating on CNTX, setting a price target of $4. Analyst Jason McCarthy of Maxim Group made this call on June 16, 2026, as the stock trades around $0.68.
Other Institutional Activity in CNTX
Soleus Capital Management, L.P. entered the scene with 6,963,141 shares valued at about $18.2 million. Octagon Capital Advisors LP also took a position with 5,250,000 shares worth approximately $13.8 million. Meanwhile, Blue Owl Capital Holdings LP trimmed its stake by 2,343,891 shares, leaving it with 5,089,015 shares valued at $13.3 million.
Context Therapeutics Inc. Stock Up 77.0%
Shares of CNTX are trading near $0.68. The stock has been of interest to several institutional investors, reflecting varied strategies in recent holdings.
$CNTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Context Therapeutics Inc.
On February 19, 2026, top executives made significant insider purchases. CFO Jennifer Lynn Minai-Azary acquired 275,000 shares, CEO Martin Lehr bought 815,000 shares, and Chief Medical Officer Karen Deborah Chagin purchased 290,000 shares. Additionally, Chief Legal Officer Alex Levit bought 270,000 shares. These transactions were not under any pre-planned trading programs.
Analysts Set New Price Targets
On June 16, 2026, Maxim Group maintained its buy rating on CNTX with a $4 target. Earlier in March, Guggenheim reiterated a buy rating with a $5 target, while Piper Sandler maintained a buy with a $7 target. The consensus among analysts remains bullish, with a strong buy recommendation.
Bottom Line
Maxim Group's reaffirmation of a buy rating for CNTX with a $4 target reflects continued optimism from analysts. Though the stock trades at a modest $0.68, institutional interest and insider buying highlight potential confidence in its prospects. As always, remember that analyst ratings are forward-looking and based on current assessments.
Get Context Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $CNTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.